Podcasts about meditec

Trader kaufen keine NVIDIA Aktien

Listen as my friend, Cindy Metrose, Vice President of Strategic Accounts and Zeiss's Digital business in the U.S. and I walk through why Zeiss has continued to be a leader in Eyecare.

Carl Zeiss Meditec Group's H1 2023/24 Financial and Operational Performance Overview In a compelling presentation, the CEO and CFO of Carl Zeiss Meditec Group detailed the company's financial and operational performance for the first half of the fiscal year 2023/24. Addressing a professional audience of stock investors, they revealed a nuanced picture of the company's unwavering resilience and strategic manoeuvres in a challenging economic landscape, instilling a sense of stability and trust. CEO's Overview of Global Economic Impact on Performance The video opens with the CEO, Dr. Markus Weber, summarizing the global economic conditions and their impact on the company. He notes a slight decrease in revenue to €947.2 million, attributing it to factors like geopolitical tensions, which affected our international sales, and supply chain disruptions, which led to production delays. Despite these challenges, strategic business units like Microsurgery showed remarkable growth, signalling robust demand and operational efficiency. CFO's Detailed Financial Analysis The CFO, Justus Felix Wehmer, then takes viewers through a detailed financial analysis, highlighting a decrease in EBIT to €108.2 million and a consolidated profit of €83.9 million. He emphasizes the strategic investments in R&D and marketing, which are crucial for long-term growth despite short-term cost pressures. Strategic Developments and Projections Significant developments, such as the acquisition of DORC BV, are discussed, underscoring Carl Zeiss Meditec's proactive expansion in ophthalmic surgical devices. Both leaders expressed a strong sense of cautious optimism for the second half of the fiscal year, forecasting a recovery in EBIT margins and revenue growth, fuelled by strategic initiatives and market expansions, fostering a positive outlook in the audience. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com

Carl Zeiss Meditec AG Q1 2023/24: Key Takeaways Introduction In this comprehensive video presentation, Carl Zeiss Meditec AG, a leading company in the medical technology sector, showcases its financial results for the first quarter of the fiscal year 2023/24. Dr. Markus Weber, the President and CEO, and the company's CFO provide valuable insights into their financial performance aimed at stock investors and stakeholders. Overview of Financial Performance The video begins with Dr Markus Weber highlighting a slight revenue growth in Q1, reaching €475.0m, a 1.0% increase from the previous year. He notes the normalisation of the order backlog at around €315m and addresses the decline in EBIT to €43.5m, a significant drop from the prior year's €60.3m. The EBIT margin also saw a decrease to 9.2%. Factors Affecting Performance Dr. Weber provides a nuanced explanation of the factors affecting their financial results. He discusses the planned measures to clear the Chinese distribution channel and the impact of currency developments on revenue and earnings. A quarter highlight was the equipment business, which saw good deliveries and improved production times, contributing positively to the financial results. Performance by Strategic Business Units The video presents a detailed analysis of the performance of strategic business units (SBUs). The Ophthalmic Devices SBU experienced a slight decrease in revenue, primarily due to a planned reduction in stock and negative currency effects. In contrast, the Microsurgery SBU showed significant revenue growth, benefiting from a reduction in the high order backlog. Regional Sales Development The presentation covers the heterogeneous sales development across different regions. The EMEA region exhibited substantial revenue growth, while the Americas experienced a decline, mainly due to a decrease in the U.S. market. The APAC region saw a slight decline in revenue, with India and Southeast Asia making positive contributions, but the Chinese market declined. Operating Results and Outlook Dr Weber discusses the operating results, noting a decrease in EBIT as expected, primarily due to a less favourable product mix. The company remains optimistic about the future, expecting revenue growth to align with market trends and a gradual recovery of the EBIT margin in the upcoming year. Conclusion The video concludes with a forward-looking statement from Dr. Weber, expressing confidence in the company's strategic direction and its ability to navigate the challenging macroeconomic environment. The detailed financial analysis provides a clear picture of Carl Zeiss Meditec's current position and prospects, making it an essential watch for investors and analysts in the medical technology industry. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. Using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Im Verlauf der vergangenen Woche haben wir drei Aktien verkauft. Darunter unter anderem eine der derzeit wohl meistdiskutierten Aktien: Nvidia. In dieser Folge erfahrt ihre alle Gründe für unsere Verkäufe. Disclaimer: Keine Anlageberatung oder -empfehlung. Nur unsere persönliche Meinung. Website: ⁠⁠www.aktienkauf-blog.de Instagram: ⁠⁠www.instagram.com/aktien.kauf Impressum: ⁠⁠www.aktienkauf-blog.de/faq

Der DAX hat gestern den Handel mit einem kleinen Plus beendet. Heute dürfte es zunächst etwas ruhiger zugehen. Die Vorgaben aus den USA sind leicht positiv. Das Bild in Asien ist diesmal gemischt.

Carl Zeiss Meditec AG FY 2022/23: Key Takeaways Introduction to Carl Zeiss Meditec's Financial Performance In this insightful video presentation, Carl Zeiss Meditec AG, a leader in medical technology, showcases its financial achievements and strategic milestones for the fiscal year 2022/23. Despite a challenging economic environment, the company reported significant revenue growth, led by Dr. Markus Weber, President and CEO. Impressive Revenue Growth Amid Economic Challenges Carl Zeiss Meditec reported a revenue increase to €2,089m, a 9.8% growth from the previous year. The company expanded market shares in its strategic business units (SBUs) – Ophthalmology and Microsurgery – while successfully reducing production and delivery times, demonstrating remarkable resilience and strategic efficiency. Performance Highlights by Business Unit The Ophthalmology SBU saw a 7.3% revenue increase, driven by a reduction in order backlogs and gains in the intraocular lens business. The Microsurgery SBU, on the other hand, recorded an 18.3% revenue growth, outperforming market expectations with enhanced equipment deliveries. Regional Growth and Contributions Carl Zeiss Meditec experienced growth across all regions. The EMEA region saw a 12.7% revenue increase, with significant contributions from Germany, France, and Southern Europe. In the Americas, revenue rose by 17.2%, particularly in the USA and Latin America. Despite challenges in China and Korea, the APAC region contributed positively to overall growth. Financial Analysis: EBIT and Strategic Investments While revenue increased, EBIT declined to €348m, influenced by a less favorable product mix and strategic investments in R&D, especially in digitalization. The EBIT margin was 16.7%, within the forecasted range. Dr. Weber highlighted these investments as crucial for future growth and stabilizing the EBIT margin above 20% in the medium term. Forecast for Fiscal Year 2023/24 For the fiscal year 2023/24, Carl Zeiss Meditec anticipates continued revenue growth, aligning with or surpassing market growth. The forecast considers potential impacts from the Chinese market and product mix adjustments. The company's commitment to research, development, and marketing investments underpins its long-term strategy. Conclusion Dr. Markus Weber's presentation not only underscores Carl Zeiss Meditec's financial resilience but also its strategic foresight in navigating a challenging economic landscape. The company's strong performance in 2022/23 and its optimistic outlook for the future solidify its position as a market leader committed to innovation and growth. ▶️ Other videos: Elevator Pitch: https://seat11a.com/investor-relations-elevator-pitch/ Company Presentation: https://seat11a.com/investor-relations-company-presentation/ Deep Dive Presentation: https://seat11a.com/investor-relations-deep-dive/ Financial Results Presentation: https://seat11a.com/investor-relations-financial-results/ ESG Presentation: https://seat11a.com/investor-relations-esg/ T&C This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on www.seat11a.com/legal and www.seat11a.com/imprint.

Es läuft weiter rund am deutschen Aktienmarkt. Der DAX markierte gestern kurz vor Handelsschluss ein neues Allzeithoch. Heut deutet sich schon der nächste Rekord an. Unter anderem könnte der DAX von den guten Vorgaben aus den USA profitieren.

Aktien-Schnelltest im Rahmen von Bernecker.TV. Michael Hüsgen im Gespräch mit Bernecker-Experte Volker Schulz ("Der Aktionärsbrief"). Diese Sendung ist eine Podcast-Variante des Schnelltests im Rahmen von Bernecker TV, Sendung vom 02.11.2023. Themen-Schlaglichter: ++ Mercedes-Benz - Bewertungsansatz ist ein Witz ++ PVA TePla - Weiter Abstand zum fairen Wert ++ Hinweis auf Bernecker-Webinar mit Oliver Kantimm und Carsten Müller am 23.11.2023 ++ Abbott - Boden in Sichtweite ++ Carl Zeiss Meditec - Abbau der Überbewertung läuft ++ Jenoptik - Chance nach überzogene Korrektur? Infos zum Bernecker-Webinar am 23.11.2023 https://ichkaufeaktien.de/webinar-231123/ ====== Anmeldung zum kostenlosen Experten-Newsletter der Bernecker-Redaktion über unsere Website: https://www.bernecker.info/newsletter

Der demographische Wandel hat viele Gesichter. Altersbedingte Augenkrankheiten gehören auf jeden Fall dazu. Carl Zeiss Meditec ist genau hier schon heute gut positioniert. Mit Blick auf die kommenden Jahre ist das deutsche Medizintechnik-Unternehmen aber gerade jetzt besonders spannend. Warum das so ist, schreibt Heiko Böhmer im aktuellen Frankfurter Investmentblog. Kapitelmarken: 00:00-02:24 Geschäftsmodell von Carl Zeiss Meditec 02:25-03:33 Marktpotenzial & stetiges Wachstum 03:34-04:16 Eigentümerstruktur bringt Stabilität 04:17-05:46 Burggraben & größter Wachstumstreiber 05:47-06:48 Warum die Aktie jetzt spannend ist? ✅✅✅ Abonnieren Sie hier den Shareholder Value Newsletter: https://www.shareholdervalue.de/newsletter ▶️ Hier geht es zum aktuellen Frankfurter Investmentblog: https://www.shareholdervalue.de/blog/author/heiko-boehmer +++RECHTLICHE HINWEISE+++ https://www.shareholdervalue.de/rechtliche-hinweise

Seit ihrem Hoch ist die Aktie von Carl Zeiss Meditec stark eingebrochen. Bietet sich jetzt ein Einstieg an? Disclaimer: Keine Anlageberatung oder -empfehlung. Nur unsere persönliche Meinung. Website: ⁠⁠www.aktienkauf-blog.de/⁠⁠ Instagram: ⁠⁠www.instagram.com/aktien.kauf/⁠ ⁠⁠⁠Impressum: ⁠⁠www.aktienkauf-blog.de/faq

In this in-depth video titled “Carl Zeiss Meditec AG Deep Dive 2023 | Cataract Workflow with IR Thu Anh”, Thu Anh, an expert from the investor relations team at Carl Zeiss Meditec AG, offers an exhaustive exploration of the company's innovative approach towards cataract treatment, a critical offering in their ophthalmology portfolio. Beginning with an introduction to cataracts, a common eye condition predominantly affecting individuals over 50, Thu Anh elaborates on how this ailment, caused by ageing, leads to the clouding of the eye's crystalline lens, progressively impairing vision. She explains that the only effective solution to this issue is to replace the clouded lens with a clear intraocular lens (IOL). This procedure is undertaken more than 25 million times globally each year. Thu Anh offers a detailed breakdown of the modern cataract treatment procedure. She explains how the process initiates with a main incision at the juncture between the cornea and sclera, followed by the careful extraction of the cloudy lens using ultrasound and suction. Subsequently, an artificial IOL is gently implanted into the clear capsular bag, restoring clear vision for the patient. The key focus of this presentation is the unveiling of Carl Zeiss Meditec's ground-breaking ‘Cataract Workflow'. This systematized, four-step process enhances clinical efficiency and improves patient outcomes. The steps encompass the assessment and education of the patient, planning pre-operative measures, conducting the surgical procedure, and carrying out follow-up processes. Multiple crucial components of this workflow are underscored. The IOL Master 700 is showcased as an exceptional diagnostic tool offering precise biometric measurements, thereby minimizing the chances of refractive surprises after surgery. The EQ Workplace is another significant asset, functioning as a data management hub that streamlines the clinical workflow by providing access to data at any time, from any place. It also aids in surgical planning, IOL calculation, and ordering. Finally, the Quatera 700, Zeiss's first phacoemulsification machine, serves as a centralized surgical platform that improves the effectiveness and efficiency of the surgical procedure. Towards the conclusion, Thu Anh shares testimonials from surgeons who have adopted this workflow and digitalization, experiencing enhanced system efficiency, reduced dependency on manual resources, and minimized transcription errors. The video wraps up with a promising outlook for the future, where Carl Zeiss Meditec seeks to standardize its cataract workflow as the primary treatment for cataract patients. The company also envisions a continued leader in the digitalization of the ophthalmic industry, projecting robust growth in this significant market segment of ophthalmology. T&C: This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

In this captivating presentation by Carl Zeiss Meditec, Sebastian Frericks, the Head of Group Finance and Investor Relations, provides an insightful overview of their operations and strategic advantages. The video focuses on the company's commitment to improving the quality of patient lives through technology and innovation, exemplified by their ground-breaking medical innovations such as Smile Technology for minimally invasive laser surgery and 4K video technology for eye surgeries.   Sebastian highlights the company's impressive financial track record, featuring a robust 10% CAGR and EBIT margin exceeding 20%. This success, he reveals, is driven by four key factors: Relentless innovation A growing base of recurring revenue Strategic focus on the high-growth Asia-Pacific region A forward-thinking approach to the digitalization of their product portfolio Zeiss Meditec's strong commitment to R&D has fostered pioneering innovations in neurosurgery and ophthalmology, positioning them at the cutting edge of medical technology. Moreover, their recurring business model, comprising 46% of their revenue, ensures a robust financial base underpinned by surgical consumables, implants, and service fees.   The company's keen focus on the Asia-Pacific region reflects an astute recognition of the high-growth potential in markets such as China. Lastly, Zeiss Meditec is harnessing the power of digitalization, connecting devices for seamless workflows, employing data management tools, and utilizing artificial intelligence for improved treatment outcomes.   In conclusion, Zeiss Meditec presents a compelling case for investors, with a track record of innovation, a steady stream of recurring revenue, a strong foothold in high-growth markets, and a future-oriented approach to digitalization. T&C: This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

We're thrilled to announce that Thu Anh Klimpke, Investor Relations of ZEISS Medical Technology Segment, is presenting a Deep Dive on the revolutionary Zeiss Smile procedure and is exploring the future of laser vision correction. Topics related to the company's strategic business units, including the myopia trend, refractive laser surgery with ZEISS Smile, and more, are also presented. During her presentation, Thu Anh provides valuable insights into the ZEISS Medical Technology Segment's structure and offerings, which include two strategic business units: Ophthalmology and Microsurgery. Within the Ophthalmology unit, ZEISS offers three key areas of focus: ophthalmic diagnostics, surgical ophthalmology, and refractive laser surgery.  Thu Anh delves into each area and closely examines the devices and consumables ZEISS offers. One of the key topics that will be discussed during the presentation is the myopia trend. According to a study, one-third of the world's population currently has myopia, with high myopia affecting one in 20 people. Thu Anh will explore the development of myopia in the coming decades, highlighting the increasing importance of laser vision correction for more and more people. Moreover, Thu Anh will discuss ZEISS's Smile technology, which stands for Small Incision Lenticule Extraction. She will explain how this technology differs from conventional laser vision correction procedures and how ZEISS offers a standalone solution. Thu Anh also provides a detailed overview of the Visa Max 800, a femtosecond system offering outstanding incision precision, speed, and a gentle treatment approach. Attendees of this presentation will gain valuable insights into the ZEISS Medical Technology Segment's offerings and how the company is leading the way in laser vision correction technology.  Don't miss out on this opportunity to learn from Thu Anh, Manager of Investor Relations for the ZEISS Medical Technology Segment. T&C This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal and imprint pages at www.seat11a.com/legal/ and www.seat11a.com/imprint/.

In this insightful video presentation, Carl Zeiss Meditec AG, a leading medical technology company, reports on its performance during the first half of the fiscal year 2022/23. Despite challenging circumstances, such as the ongoing COVID-19 pandemic and strained global supply chains, the company achieved a remarkable 13.9% growth, generating around €974.5m in revenue. However, this robust revenue growth was offset by a decline in earnings before interest and taxes (EBIT), which dropped to €143.9m from the prior year's €177.3m, primarily due to an unfavourable product mix and rising operational costs.   Notably, the Americas region recorded the most substantial growth, with revenue surging by an impressive 27.6%. The company's strategic business units (SBUs) in Ophthalmology and Microsurgery contributed significantly to this growth. In contrast, the EBIT margin shrank to 14.8% from 20.7% in the previous year, largely due to the pandemic's impact on the Chinese market, increased investment in research and development, higher procurement costs, and rising labour costs.   Despite the decrease in EBIT, the company's CEO, Dr Markus Weber, expresses satisfaction with the company's performance and reaffirms the company's commitment to strategic investments in research and development, supply chain improvements, and shortening delivery times. Looking ahead, Carl Zeiss Meditec AG has consolidated its projections for the fiscal year 2022/23, expecting revenue to increase to around €2.1 billion, with the EBIT margin anticipated to be between 17-20%. T&C: This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

Aujourd'hui sur Investisseur.TV Arnaud Chesnay Gérant de fonds de Athymis Trendsetters EuropeHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Welcome to seat11a, in today's podcast we are presenting Markus Weber, CEO, and Justus Felix Wehmer, CFO of Carl Zeiss Meditech AG. Markus and Justus will present the Financials: Q3-2021/22 of Carl Zeiss Meditech ▶️ Visit us: https://seat11a.com/ Company Profile The Medical Technology activities of ZEISS are bundled under the umbrella of the MDAX- and TecDAX-listed company Carl Zeiss Meditec AG. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world in major markets. The company can also exploit the Carl Zeiss group`s powerful global distribution network. Two Pillars of Business & Markets: The main activities of Carl Zeiss Meditec AG are located in the field of Ophthalmology and Microsurgery In Ophthalmology, the Company offers mainly products and solutions for the diagnosis and treatment of eye diseases, as well as systems and consumables for cataract, retinal and refractive surgery. In Microsurgery the Carl Zeiss Meditec Group provides visualization solutions for minimally invasive surgical treatments. Markets: The Carl Zeiss Meditec Group has operations all over the world. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world's most important markets. Milestones & Innovations: Research and development plays an important role within the Carl Zeiss Meditec Group. Our objective is to enable our customers and physicians to continuously improve treatment results through improvements in efficiency and innovative new products ---------------------------- ▶️ Visit us: https://seat11a.com/ ---------------------------- ▶️ Other videos: Elevator Pitches: https://seat11a.com/media-type/elevator-pitch/ Company Presentations: https://seat11a.com/media-type/presentation/ Financial Results: https://seat11a.com/media-type/financials/ The Big Conversations: https://seat11a.com/media-type/conversation/ ESG Topics: https://seat11a.com/media-type/esg/ Product Highlights: https://seat11a.com/media-type/products/ ----------------------------- ▶️ About seat11a: seat11a is the next-generation roadshow for listed companies. We democratize financial intelligence by offering listed companies an investor video platform to address their message to Institutional and Professional Investors anywhere, anytime. ✅ Disclaimer: this publication is just for informational purposes only – it is not considered to give any investment advice! You agree to www.seat11a.com/legal/ and www.seat11a.com/imprint/

Die Leitzinserhöhung der EZB hat den DAX gestern kurz durcheinander geschüttelt. Am Ende ging der Leitindex mit einem kleinen Verlust aus dem Handel. Heute wird er zunächst schwächer erwartet - trotz guter Vorgaben aus den USA.

Welcome to seat11a, in this podcast we are presenting Markus Weber, CEO, and Justus Felix Wehmer, CFO of Carl Zeiss Meditech AG. Markus and Justus will present the Financials: H1-2021/22 of Carl Zeiss Meditech ▶️ Visit us: https://seat11a.com/ Company Profile The Medical Technology activities of ZEISS are bundled under the umbrella of the MDAX- and TecDAX-listed company Carl Zeiss Meditec AG. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world in major markets. The company can also exploit the Carl Zeiss group`s powerful global distribution network. Two Pillars of Business & Markets: The main activities of Carl Zeiss Meditec AG are located in the field of Ophthalmology and Microsurgery In Ophthalmology, the Company offers mainly products and solutions for the diagnosis and treatment of eye diseases, as well as systems and consumables for cataract, retinal and refractive surgery. In Microsurgery the Carl Zeiss Meditec Group provides visualization solutions for minimally invasive surgical treatments. Markets: The Carl Zeiss Meditec Group has operations all over the world. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world's most important markets. Milestones & Innovations: Research and development plays an important role within the Carl Zeiss Meditec Group. Our objective is to enable our customers and physicians to continuously improve treatment results through improvements in efficiency and innovative new products ---------------------------- ▶️ Visit us: https://seat11a.com/ ---------------------------- ▶️ Other videos: Elevator Pitches: https://seat11a.com/media-type/elevator-pitch/ Company Presentations: https://seat11a.com/media-type/presentation/ Financial Results: https://seat11a.com/media-type/financials/ The Big Conversations: https://seat11a.com/media-type/conversation/ ESG Topics: https://seat11a.com/media-type/esg/ Product Highlights: https://seat11a.com/media-type/products/ ----------------------------- ▶️ About seat11a: Seat11a is the next-generation roadshow for listed companies. We democratize financial intelligence by offering listed companies an investor video platform to address their message to Institutional and Professional Investors anywhere, anytime. ----------------------------- ▶️ For business inquiries: info@seat11a.com ----------------------------- ✅ Disclaimer: this publication is just for informational purposes only – it is not considered to give any investment advice! You agree to www.seat11a.com/legal/ and www.seat11a.com/imprint/

Jag pratar med Bo Karlstedt från MediTec om deras genialiska produkt Allerginius som du kan använda för att uptäcka vilka allergener på en hund är du allergisk till och sen matcha också det med hunden du vill köpa. Du kan alltså testa den hunden du köper också, för att se om den inte har/har den allergen du själv är allergisk mot. Har du själv erfarenhet av att vara allergisk och skaffa hund? Berätta gärna på mina sociala medier om det. Jag är sååå nyfiken. Om du gillar vad jag pratar om i podden och vad jag pratar om med mina gäster sprid podden vidare genom att dela den på dina sociala medier. Du kan också hjälpa mig genom att rejta podden i din podcast app, eller där du lyssnar på poddar. Klicka på klock ikonen om du vill få notiser när nya avsnitt publiceras. Hör av dig till mig och berätta vad vill du höra här i podden, på IG: https://www.instagram.com/valpkonsulten/ eller FB: https://www.facebook.com/valpkonsultpodden. Du kan också komma i kontakt med mig via min hemsida www.valpkonsulten.com.

Carl Zeiss Meditec, Inc. v. Topcon Medical Systems, Inc.

Carl Zeiss Meditec, Inc. v. Topcon Medical Systems, Inc.

Welcome to seat11a, in today's podcast we are presenting Markus Weber, CEO, and Justus Felix Wehmer, CFO of Carl Zeiss Meditech AG. Markus and Justus will present the Financials: Q1-2021/22 of Carl Zeiss Meditech ▶️ Visit us: https://seat11a.com/ ▶️ In this podcast the CEO and CFO will explain: 00:08 Introduction 00:21 Q1-2021/22: Overview 01:33 Q1-2021/22: Financials 02:22 New Products 02:50 Q1-2021/22: Outlook Company Profile The Medical Technology activities of ZEISS are bundled under the umbrella of the MDAX- and TecDAX-listed company Carl Zeiss Meditec AG. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world in major markets. The company can also exploit the Carl Zeiss group`s powerful global distribution network. Two Pillars of Business & Markets: The main activities of Carl Zeiss Meditec AG are located in the field of Ophthalmology and Microsurgery In Ophthalmology, the Company offers mainly products and solutions for the diagnosis and treatment of eye diseases, as well as systems and consumables for cataract, retinal and refractive surgery. In Microsurgery the Carl Zeiss Meditec Group provides visualization solutions for minimally invasive surgical treatments. Markets: The Carl Zeiss Meditec Group has operations all over the world. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world's most important markets. Milestones & Innovations: Research and development plays an important role within the Carl Zeiss Meditec Group. Our objective is to enable our customers and physicians to continuously improve treatment results through improvements in efficiency and innovative new products ---------------------------- ▶️ Visit us: https://seat11a.com/ ---------------------------- ▶️ Other videos: Elevator Pitches: https://seat11a.com/media-type/elevator-pitch/ Company Presentations: https://seat11a.com/media-type/presentation/ Financial Results: https://seat11a.com/media-type/financials/ The Big Conversations: https://seat11a.com/media-type/conversation/ ESG Topics: https://seat11a.com/media-type/esg/ Product Highlights: https://seat11a.com/media-type/products/ ----------------------------- ▶️ About seat11a: Seat11a is the next generation roadshow for listed companies. We democratize financial intelligence by offering listed companies an investor video platform to address their message to Institutional and Professional Investors anywhere, anytime. ----------------------------- ▶️ For business inquiries: info@seat11a.com ----------------------------- ✅ Disclaimer: this publication is just for informational purposes only – it is not considered to give any investment advice! You agree to www.seat11a.com/legal/ and www.seat11a.com/imprint/

Welcome to seat11a, in today's podcast we are presenting Sebastian Frericks, IR of Carl Zeiss. Sebastian will present the Elevator Pitch ▶️ Visit us: https://seat11a.com/ ▶️ In this podcast Sebastian explains: What is Carl Zeiss Meditech about? Financial Track Record Four Reasons to invest: 1. Innovation 2. Recurring Revenue 3. Asia-Pacific 4. Digitalization Summary Outlook Company Profile The Medical Technology activities of ZEISS are bundled under the umbrella of the MDAX- and TecDAX-listed company Carl Zeiss Meditec AG. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world in major markets. The company can also exploit the Carl Zeiss group`s powerful global distribution network. Two Pillars of Business & Markets: The main activities of Carl Zeiss Meditec AG are located in the field of Ophthalmology and Microsurgery In Ophthalmology, the Company offers mainly products and solutions for the diagnosis and treatment of eye diseases, as well as systems and consumables for cataract, retinal and refractive surgery. In Microsurgery the Carl Zeiss Meditec Group provides visualization solutions for minimally invasive surgical treatments. Markets: The Carl Zeiss Meditec Group has operations all over the world. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world's most important markets. Milestones & Innovations: Research and development plays an important role within the Carl Zeiss Meditec Group. Our objective is to enable our customers and physicians to continuously improve treatment results through improvements in efficiency and innovative new products ---------------------------- ▶️ Visit us: https://seat11a.com/ ---------------------------- ▶️ Other videos: Elevator Pitches: https://seat11a.com/media-type/elevator-pitch/ Company Presentations: https://seat11a.com/media-type/presentation/ Financial Results: https://seat11a.com/media-type/financials/ The Big Conversations: https://seat11a.com/media-type/conversation/ ESG Topics: https://seat11a.com/media-type/esg/ Product Highlights: https://seat11a.com/media-type/products/ ----------------------------- ▶️ About seat11a: Seat11a is the next generation roadshow for listed companies. We democratize financial intelligence by offering listed companies an investor video platform to address their message to Institutional and Professional Investors anywhere, anytime. ----------------------------- ▶️ For business inquiries: info@seat11a.com ----------------------------- ✅ Disclaimer: this publication is just for informational purposes only – it is not considered to give any investment advice! You agree to www.seat11a.com/legal/ and www.seat11a.com/imprint/

Welcome to seat11a, in today's podcast we are presenting Justus Felix Wehmer, CFO of Carl Zeiss Meditec AG Justus joins us in The Big Conversation ▶️ Visit us: https://seat11a.com/ Watch the entire Video Elevator Pitch here: https://seat11a.com/title/carl-zeiss-meditec-conversation-wehmer/ ▶️ In this podcast Justus talks about the following topics: Key factors that make Carl Zeiss Meditec an attractive investment. Parent company and the relationship. Business units and underlying markets Growth drivers in ophthalmic surgery. Opportunity in digitalization. Competitive Landscape by market and segment. Key geographic Exposures / Portfolio by Region. Opportunities and risks in China. Growth opportunity in the US market. M&A opportunities in your sector. Latest financial outlook. ▶️ Company Profile The Medical Technology activities of ZEISS are bundled under the umbrella of the MDAX- and TecDAX-listed company Carl Zeiss Meditec AG. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world in major markets. The company can also exploit the Carl Zeiss group`s powerful global distribution network. Two Pillars of Business & Markets: The main activities of Carl Zeiss Meditec AG are located in the field of Ophthalmology and Microsurgery In Ophthalmology, the Company offers mainly products and solutions for the diagnosis and treatment of eye diseases, as well as systems and consumables for cataract, retinal and refractive surgery. In Microsurgery the Carl Zeiss Meditec Group provides visualization solutions for minimally invasive surgical treatments. Markets: The Carl Zeiss Meditec Group has operations all over the world. With headquarters in Jena (Germany) and operating sites and subsidiaries in Germany, France, Spain, the USA and Japan the company has a direct presence in the world's most important markets. Milestones & Innovations: Research and development plays an important role within the Carl Zeiss Meditec Group. Our objective is to enable our customers and physicians to continuously improve treatment results through improvements in efficiency and innovative new products T&C: this publication is for informational purposes only – it is not considered as investment advice! You agree to: www.seat11a.com/legal/ www.seat11a.com/imprint/

Zum Jahresende hin nimmt zwar die Anzahl der Termine allmählich ab, doch auch in der kommenden Woche wird es einige wichtige Ereignisse geben. So wird bei der Dezember-Sitzung der EZB mit einigen weitreichenden Entscheidungen und Weichenstellungen gerechnet. Was zu erwarten ist - und was nicht, erörtert Mark Schrörs, Leiter des Wirtschaftspolitikressorts und Währungspolitischer Korrespondent der Börsen-Zeitung, im Gespräch mit Franz Công Bùi, der im Anschluss daran mit seiner Kollegin Christiane Lang Details zu weiteren Themen der Woche wie dem EU-Gipfel, die Perspektiven der Maschinenbaubranche und den Jahreszahlen von Carl Zeiss Meditec vorstellt.

Dieses Jahr konnte die Carl Zeiss Meditec AG einen deutlichen Umsatzanstieg von 200 Millionen Euro im Vergleich zum letzten Jahr verzeichnen. Von Konjunkturflaute lässt sich beim Jenaer Unternehmen nichts sehen. Der börsennotierte Medizintechnikkonzern konnte seinen finanziellen Wachstumstrend der letzten Jahre auch in 2019 deutlich ausbauen. Rund 14 % mehr Umsatz gab es für den Konzern in diesem Jahr. Das sind fast 1,5 Milliarden Euro. Damit einher geht eine Steigerung des Gewinns um 27 % von rund 34 Millionen Euro auf 160,6 Millionen Euro. Der Konzern beschäftigt etwa 3.000 Mitarbeiter_innen im In- und Ausland für die Entwicklung und Produktion von Operationsmikroskopen, Lasern und künstlichen Linsen für Patienten_innen mit Grauem Star. Im kommenden Jahr plant der Konzern stark in Forschung und Entwicklung, sowie in Marketing und Vertrieb zu investieren, um eine weitere Beschleunigung des Wachstums im kommenden Jahr zu ermöglichen. Denn ihr Ziel ist es, schneller als der Markt zu wachsen.

I det här avsnittet gästas Sara och Helena av Bo Karlstedt och Hans Grönlund från MediTec. Hans Grönlund är forskare som inriktat sig speciellt på forskning kring just pälsdjursallergi och grundade bolaget MediTec där Bo Karlstedt är VD. Tillsammans berättar dom i det här avsnittet om vad allergi är, tar upp myten om allergivänliga hundar, berättar hur man kan göra för att göra sin hund mindre allergen och mycket mer. De berättar också om det schampo och balsam som de tagit fram under namnet Allergenius, som minskar hundens allergener drastiskt. Hos allergenius finns även test-kit att beställa för att se vilka allergener hos hund som man själv inte tål, samt vilka allergener en viss hundindivid bär på.  Sara och Helena hoppas att du får många frågor besvarade i och med detta avsnitt, och att lyssnaren blir inspirerad att minska mängden allergener från oss hundmänniskor med hopp om ett mer tillgängligt samhälle för både allergiker och hundar - sida vid sida. 

Deltina Hay from Elearning Delta, and past Board Chair of IBPA, talks about the benefits and methods of extending your book’s content and repurposing it onto elearning platforms. This podcast is for anyone with instructional materials of any kind: crafts, marketing, cooking, sales—just about any field where you’ve got information to deliver in a structured learning format. Subjects discussed include: what kinds of books lend themselves to elearning? do publishers generally start with a book to adapt, or an idea they want to get across? elearning as a calling card to demonstrate your credentials as an expert what kinds of skills do you need for DIY; can “ordinary” folks master the tools? when should you hire a professional, and why should you? the cheap route: YouTube, Instagram hallmarks of a professional package: quality, certification, assessments, worksheets elearning beyond the book: you have to provide more than what’s already in print finding the best elearning system for your content marketing and monetizing sell it on your own or in a marketplace? publicizing your elearning program through blogging and social media what does it cost to make a 1-hour elearning program? what should your charge for your elearning course (beware of cheap competition!) how long did it take Deltina to produce a 10-minute video (you may not believe the answer!) study the marketplace to figure out what your competitors are up to is there still a need for books? Elearning tools and websites mentioned in the podcast are: Articulate Storyline: https://articulate.com/360/storyline Adobe Captivate: https://www.adobe.com/products/captivate.html Camtasia: https://www.techsmith.com/video-editor.html Udemy Online Courses: https://www.udemy.com/ DeltinaU: https://deltinau.com/ == Participants Deltina Hay is the Director of Technology and Elearning Development at Elearning Delta. She is a programmer, web developer, software aficionado, writer, teacher, digital strategist, and instructional designer. For nearly 30 years, Deltina has helped businesses of all sizes with their custom programming, database management, web development, search optimization, and social media marketing. Some of her past clients include Real Simple Magazine, Nestle Toll House, Victoria’s Secret, H-E-B, Kraft, Hachette Books, RaceWorldTV, and the University of Missouri. Deltina is the author of three books on social media, the mobile web, and search optimization. Her first book, The Social Media Survival Guide, is used as a textbook in colleges and universities all over the world. For the past five years, Deltina has applied her diverse skill set to the education industry. She developed and taught the graduate-level social media certificate program for Drury University, and has designed and developed social media, digital marketing, mobile marketing, and search optimization certification programs for several online colleges and training sites, including 360Training, Meditec, and WorldEducation. Deltina’s elearning development company, DeltinaU, produces and publishes courses in digital and mobile marketing, search optimization, and web development. There are more than 20 courses to choose from and successful students are awarded a “Certificate in Digital Marketing”. You can reach Deltina at Elearning Delta: http://elearningdelta.com/ support@elearningdelta.com Peter Goodman (host) is publisher of Stone Bridge Press in Berkeley, California. He began his publishing career in Tokyo, Japan, in 1976. A longtime member of IBPA, he has served on the IBPA board and as IBPA board chair.

Carl Zeiss Meditec continues to add top talent. Andrew Chang, who managed US sales at B&L, joins the growing group bringing him together with Unit Head Jim Mazzo.

Meet the newest Master of the Industry. Jim Mazzo, who has led divisions, spin-outs, and start-ups, now leads what looks to be a new leader in ophthalmology. Hear how Mazzo views this new opportunity for Zeiss and himself.

Meet the newest Master of the Industry. Jim Mazzo, who has led divisions, spin-outs, and start-ups, now leads what looks to be a new leader in ophthalmology. Hear how Mazzo views this new opportunity for Zeiss and himself.

Hoy, Salud y Tecnología en Corferias. Porque no hay señal HD de la TV Colombiana en los sistemas de TV Paga.Helados y café. Celulares, música y video comparten espacio.Ya sabe como reclamar los minutos que pierde en las llamadas caídas?

Nurse Cindy Garrett is the educational leader for MEDITEC. The Medical Innovation Technology Education Center is an initiative developed by Texas Valley Communities Foundation to provide students an experience in high level medical technology to further enhance learning in the Sciences and prepare students for a future in the Science, Technology, Engineering and Medical Fields. School districts must begin concentrating on innovative ways to further engage students in science and the health care industry, the fastest growing workforce demand. The use of medical simulation is an ever-growing practice among post-secondary institutions; however, this is used sparingly across the nation with secondary students but has proven to be a tool for reinforcing teaching in the science classrooms. Real world applications allow students to make connections between what is taught from a textbook and applied in the industry and show students the relevance of what is being learned daily. MEDITEC integrates high-fidelity human simulation technology in a way that intercepts science curriculum, connecting biology, anatomy and physiology in a real world setting. This technology provides a unique opportunity for experimentation and inquiry of understanding the practice of medicine. Specific case scenarios accentuate classroom curriculum and problem solving exercises chosen to foster biomedical literacy and an interest in science and scientific inquiry. AREAS of EXPERTISE • Registered Nurse • Bachelors of Science in Nursing • Texas Education Agency Certification • Vocation Health Science Technology • Grade 6 – 12 • Advance Cardiac Life Support (ACLS) • First Aid/Cardiopulmonary Resuscitation (CPR) • IV insertion • Patient Assessment • Healthcare Simulation Training